---
title: "Ocrevus (ocrelizumab) in multiple sclerosis: Real-world evidence questions"
description: "Real-world evidence questions on Ocrevus (ocrelizumab) in multiple sclerosis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Ocrevus vs Kesimpta (ofatumumab): how do adherence and persistence compare in claims data? 1 question quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/real-world-evidence"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Ocrevus (ocrelizumab) in multiple sclerosis: Real-world evidence questions

Manufacturer: Genentech, Inc.  
Prescribing information: [Ocrevus](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf), [Ocrevus Zunovo](https://www.gene.com/download/pdf/ocrevus_zunovo_prescribing.pdf)

Questions that apply to every indication of Ocrevus are on [Ocrevus (ocrelizumab), all indications](https://www.evicenter.com/medical-information/ocrevus).

## Real-world evidence

<a id="ocrevus-adherence-vs-kesimpta"></a>

### Ocrevus vs Kesimpta (ofatumumab): how do adherence and persistence compare in claims data?

Applies to: Relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in adults (OCREVUS intravenous)

> “OCREVUS (ocrelizumab) and Kesimpta<sup>®</sup> (ofatumumab) were studied using real-world US commercial, Medicare, and Medicaid claims data from IQVIA PharMetrics<sup>®</sup> Plus”

Source: [OCREVUS: Dosing and Administration, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/dosing-administration.html#:~:text=OCREVUS%20%28ocrelizumab%29%20and,Plus)

> “Inclusion criteria included: patients ≥18 years of age with a diagnosis of MS who initiated OCREVUS or Kesimpta using a confirmed<sup>†</sup> loading dose between August 20, 2020, and December 31, 2021; at least ≥12 months of continuous health plan enrollment prior to treatment initiation (index date)<sup>‡</sup> with 24 months of follow-up data”

Source: [OCREVUS: Dosing and Administration, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/dosing-administration.html#:~:text=Inclusion%20criteria%20included%3A%20patients%20%E2%89%A518,24%20months%20of%20follow%2Dup%20data)

> “In this sensitivity analysis, adjustments for overlapping days' supply were not made for either OCREVUS or Kesimpta”

Source: [OCREVUS: Dosing and Administration, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/dosing-administration.html#:~:text=In%20this%20sensitivity%20analysis%2C%20adjustments,for%20either%20OCREVUS%20or%20Kesimpta)

> “Adherence was calculated based on proportion of days covered (PDC), with ≥80% considered adherent to the DMT initiated”

Source: [OCREVUS: Dosing and Administration, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/dosing-administration.html#:~:text=Adherence%20was%20calculated%20based%20on,adherent%20to%20the%20DMT%20initiated)

> “Adherence
>
> Among patients with 2 years of follow-up
>
> 27% relative risk reduction
>
> of nonadherence for OCREVUS vs KESIMPTA patients
>
> RR=0.73 (95% CI: 0.60-0.89)
>
> Persistence
>
> Among patients with 2 years of follow-up
>
> 18% relative risk reduction
>
> of nonpersistence for OCREVUS vs KESIMPTA patients
>
> RR=0.82 (95% CI: 0.68-0.98)”

Source: [OCREVUS: Dosing and Administration, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/dosing-administration.html#:~:text=Among%20patients%20with%202%20years%20of%20follow%2Dup,RR%3D0.82%20%2895%25%20CI%3A%200.68%2D0.98%29)

> “<sup>§</sup>Results based on a sensitivity analysis from a retrospective cohort study using fully adjudicated medical and pharmacy claims from August 2019 through December 2023 extracted from the IQVIA PharMetrics Plus database.<sup>5</sup>”

Source: [OCREVUS: Dosing and Administration, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/dosing-administration.html#:~:text=based%20on%20a%20sensitivity%20analysis,from%20the%20IQVIA%20PharMetrics%20Plus)

> “Analyses using administrative pharmacy and medical claims data are dependent on the accuracy and specificity of information provided
> Adherence and persistence were calculated based on the administration schedule recommended in each product’s Prescribing Information and days’ supply as shown in claims for Kesimpta; instances where prescribing patterns differ from the FDA-approved administration schedules, adherence and persistence may be misclassified
> Differences in dosing and pharmacodynamics should be considered when making direct comparisons between DMTs
> Kesimpta is a monthly subcutaneous injection; please refer to the PI for Kesimpta for additional information<sup>6</sup>
> Claims data have inherent limitations:
> Unable to ascertain if patients on self-administered medications, including Kesimpta, took DMT as prescribed”

Source: [OCREVUS: Dosing and Administration, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/dosing-administration.html#:~:text=Analyses%20using%20administrative%20pharmacy%20and,Kesimpta%2C%20took%20DMT%20as%20prescribed)

> “Real-world adherence and persistence rates should not be considered as a comparison of safety and efficacy”

Source: [OCREVUS: Dosing and Administration, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/dosing-administration.html#:~:text=Real%2Dworld%20adherence%20and%20persistence%20rates,comparison%20of%20safety%20and%20efficacy)

## Related pages
- [Medical information: Ocrevus (ocrelizumab): Multiple sclerosis](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis)
- [Indication](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/storage-and-supply)
